Zevra Therapeutics, Inc. Unrealized Gain (Loss) on Investments
Zevra Therapeutics, Inc. (ZVRA) reported Unrealized Gain (Loss) on Investments of $149.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnInvestments · last filed 2026-03-09
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2025-12-31 was $30.00K.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2025-09-30 was $124.00K, a 38.00% decline year-over-year.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2025-06-30 was $3.00B.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for the quarter ending 2025-03-31 was -$3.00B.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2025 was $149.00K.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2024 was -$18.00K, a 103.00% decline from fiscal 2023.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2023 was $600.00K.
- Zevra Therapeutics, Inc. unrealized gain (loss) on investments for fiscal 2022 was -$600.00K.
| Period end | Unrealized Gain (Loss) on Investments 3 month | Unrealized Gain (Loss) on Investments 6 month | Unrealized Gain (Loss) on Investments 9 month | Unrealized Gain (Loss) on Investments 12 month | Unrealized Gain (Loss) on Investments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $154.00K derived: sum of 2 quarters · filed 2026-03-09 | $3.00B derived: sum of 3 quarters · filed 2026-03-09 | $149.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.00B derived: sum of 2 quarters · filed 2025-11-05 | $119.00K 10-Q · filed 2025-11-05 | $1.00K derived: sum of 4 quarters · filed 2026-03-09 | |
| 2025-06-30 | $3.00B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$5.00K 10-Q · filed 2025-08-12 | -$123.00K derived: sum of 3 quarters · filed 2026-03-09 | $77.00K derived: sum of 4 quarters · filed 2026-03-09 | |
| 2025-03-31 | -$3.00B 10-Q · filed 2025-05-13 | -$3.00B derived: sum of 2 quarters · filed 2026-03-09 | -$3.00B derived: sum of 3 quarters · filed 2026-03-09 | -$3.00B derived: sum of 4 quarters · filed 2026-03-09 | |
| 2024-12-31 | -$118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $82.00K derived: sum of 2 quarters · filed 2026-03-09 | $82.00K derived: sum of 3 quarters · filed 2026-03-09 | -$18.00K 10-K · filed 2026-03-09 | $18.00B 10-K · filed 2025-03-12 |
| 2024-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $200.00K derived: sum of 2 quarters · filed 2024-11-13 | $100.00K 10-Q · filed 2024-11-13 | $1.20M derived: sum of 4 quarters · filed 2025-03-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$100.00K 10-Q · filed 2024-08-14 | $1.00M derived: sum of 3 quarters · filed 2025-03-12 | $800.00K derived: sum of 4 quarters · filed 2025-03-12 | |
| 2024-03-31 | -$100.00K 10-Q · filed 2024-05-09 | $1.00M derived: sum of 2 quarters · filed 2025-03-12 | $800.00K derived: sum of 3 quarters · filed 2025-03-12 | $900.00K derived: sum of 4 quarters · filed 2025-03-12 | |
| 2023-12-31 | $1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $900.00K derived: sum of 2 quarters · filed 2025-03-12 | $1.00M derived: sum of 3 quarters · filed 2025-03-12 | $600.00K 10-K · filed 2025-03-12 | |
| 2023-09-30 | -$200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$100.00K derived: sum of 2 quarters · filed 2023-11-07 | -$500.00K 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$300.00K 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | -$400.00K 10-Q · filed 2023-05-15 | ||||
| 2022-12-31 | -$600.00K 10-K · filed 2024-04-01 | -$577.00K 10-K · filed 2023-03-07 | |||
| 2021-12-31 | -$13.00K 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |